Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 247Observational 27Expanded_access 1

Sponsor

Cancer Type

Lymphoid 5Sarcoma 2Plasma cell 2Other neoplasm 1Other hematologic neoplasm 1Myeloid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Melanoma 21Carcinoma, Non-Small-Cell Lung 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Glioblastoma 3Colorectal Neoplasms 3Carcinoma, Basal Cell 3Uveal Melanoma 2Prostatic Neoplasms 2Lymphoma, T-Cell, Cutaneous 2Glioma 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Sarcoma 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Liver Neoplasms 1Keratosis 1Hodgkin Disease 1Hematologic Diseases 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory 1Cholangiocarcinoma 1

Interventions

Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Hodgkin Disease × Dermatologic × Clear all
NCT01196208 2020-09-21

A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

Seagen Inc.

No longer available
DermatologicLymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡